Lymphoid enhancer-binding factor 1 mRNA (LEF1 mRNA)

Lymphoid enhancer-binding factor 1 (LEF1) mRNA is the transcript encoding a key transcription factor within the canonical Wnt/beta-catenin signaling pathway. LEF1 is essential for embryonic development, particularly in the formation of the hair follicle, tooth, and mammary glands, as well as for the differentiation of T and B lymphocytes. In many human cancers, including chronic lymphocytic leukemia (CLL), colorectal cancer, and breast cancer, LEF1 mRNA is aberrantly overexpressed, where it promotes tumor cell proliferation, survival, and the epithelial-mesenchymal transition (EMT) associated with metastasis. As a therapeutic target, LEF1 mRNA is being explored through RNA interference (siRNA) and antisense oligonucleotide (ASO) technologies designed to degrade the transcript and reduce the levels of the oncogenic protein. While no RNA-based drugs targeting LEF1 are currently approved for clinical use, experimental studies have demonstrated that silencing LEF1 mRNA can effectively induce apoptosis and sensitize cancer cells to chemotherapy. Therapeutic challenges include the potential for off-target effects and the necessity of maintaining normal Wnt signaling in healthy stem cell populations.

Other names

LEF-1 mRNATCF1-alpha mRNALymphoid enhancer-binding factor 1 transcriptTCF7L3 mRNAT cell-specific transcription factor 1-alpha mRNA

RNA interference (RNAi) or antisense inhibition leading to mRNA degradation or translational repression